Edgewise Therapeutics, Inc. Increase (Decrease) in Other Accrued Liabilities
Edgewise Therapeutics, Inc. (EWTX) reported Increase (Decrease) in Other Accrued Liabilities of $3.45 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherAccruedLiabilities · last filed 2026-08-06
- Edgewise Therapeutics, Inc. increase (decrease) in other accrued liabilities for the quarter ending 2026-06-30 was $2.81M.
- Edgewise Therapeutics, Inc. increase (decrease) in other accrued liabilities for the quarter ending 2026-03-31 was $635.00K, a 420.49% increase year-over-year.
- Edgewise Therapeutics, Inc. increase (decrease) in other accrued liabilities for the quarter ending 2025-12-31 was $1.44M, a 30.78% increase year-over-year.
- Edgewise Therapeutics, Inc. increase (decrease) in other accrued liabilities for the quarter ending 2025-09-30 was $548.00K, a 44.48% decline year-over-year.
- Edgewise Therapeutics, Inc. increase (decrease) in other accrued liabilities for fiscal 2025 was $691.00K, a 40.33% decline from fiscal 2024.
- Edgewise Therapeutics, Inc. increase (decrease) in other accrued liabilities for fiscal 2024 was $1.16M, a 120.15% increase from fiscal 2023.
- Edgewise Therapeutics, Inc. increase (decrease) in other accrued liabilities for fiscal 2023 was $526.00K, a 60.63% decline from fiscal 2022.
- Edgewise Therapeutics, Inc. increase (decrease) in other accrued liabilities for fiscal 2022 was $1.34M, a 51.35% decline from fiscal 2021.
| Period end | Increase (Decrease) in Other Accrued Liabilities 3 month | Increase (Decrease) in Other Accrued Liabilities 6 month | Increase (Decrease) in Other Accrued Liabilities 9 month | Increase (Decrease) in Other Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $3.45M 10-Q · filed 2026-08-06 | $4.88M derived: sum of 3 quarters · filed 2026-08-06 | $5.43M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $635.00K 10-Q · filed 2026-05-07 | $2.07M derived: sum of 2 quarters · filed 2026-05-07 | $2.62M derived: sum of 3 quarters · filed 2026-05-07 | $1.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.98M derived: sum of 2 quarters · filed 2026-02-26 | $569.00K derived: sum of 3 quarters · filed 2026-08-06 | $691.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $548.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$867.00K derived: sum of 2 quarters · filed 2026-08-06 | -$745.00K 10-Q · filed 2025-11-06 | $353.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$1.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.29M 10-Q · filed 2026-08-06 | -$195.00K derived: sum of 3 quarters · filed 2026-08-06 | $792.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $122.00K 10-Q · filed 2026-05-07 | $1.22M derived: sum of 2 quarters · filed 2026-05-07 | $2.21M derived: sum of 3 quarters · filed 2026-05-07 | $1.38M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.08M derived: sum of 2 quarters · filed 2026-02-26 | $1.26M derived: sum of 3 quarters · filed 2026-02-26 | $1.16M 10-K · filed 2026-02-26 |
| 2024-09-30 | $987.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $162.00K derived: sum of 2 quarters · filed 2025-11-06 | $60.00K 10-Q · filed 2025-11-06 | $450.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$825.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$927.00K 10-Q · filed 2025-08-07 | -$537.00K derived: sum of 3 quarters · filed 2026-02-26 | -$1.35M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$102.00K 10-Q · filed 2025-05-08 | $288.00K derived: sum of 2 quarters · filed 2026-02-26 | -$523.00K derived: sum of 3 quarters · filed 2026-02-26 | $54.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $390.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$421.00K derived: sum of 2 quarters · filed 2026-02-26 | $156.00K derived: sum of 3 quarters · filed 2026-02-26 | $526.00K 10-K · filed 2026-02-26 |
| 2023-09-30 | -$811.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$234.00K derived: sum of 2 quarters · filed 2024-11-07 | $136.00K 10-Q · filed 2024-11-07 | $1.66M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $577.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $947.00K 10-Q · filed 2024-08-08 | $2.47M derived: sum of 3 quarters · filed 2024-08-08 | $2.04M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $370.00K 10-Q · filed 2024-05-09 | $1.90M derived: sum of 2 quarters · filed 2024-05-09 | $1.46M derived: sum of 3 quarters · filed 2024-05-09 | $2.55M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $1.53M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $1.09M derived: sum of 2 quarters · filed 2024-02-22 | $2.18M derived: sum of 3 quarters · filed 2024-02-22 | $1.34M 10-K · filed 2024-02-22 |
| 2022-09-30 | -$434.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $655.00K derived: sum of 2 quarters · filed 2023-11-09 | -$191.00K 10-Q · filed 2023-11-09 | -$742.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $1.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $243.00K 10-Q · filed 2023-08-10 | -$308.00K derived: sum of 3 quarters · filed 2023-08-10 | $1.57M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$846.00K 10-Q · filed 2023-05-11 | -$1.40M derived: sum of 2 quarters · filed 2023-05-11 | $485.00K derived: sum of 3 quarters · filed 2023-05-11 | $885.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$551.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $1.33M derived: sum of 2 quarters · filed 2023-02-23 | $1.73M derived: sum of 3 quarters · filed 2023-02-23 | $2.75M 10-K · filed 2023-02-23 |
| 2021-09-30 | $1.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $2.28M derived: sum of 2 quarters · filed 2022-11-03 | $3.30M 10-Q · filed 2022-11-03 | $4.17M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $1.42M 10-Q · filed 2022-08-04 | $2.29M derived: sum of 3 quarters · filed 2022-08-04 | $2.40M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $1.01M 10-Q · filed 2022-05-11 | $1.89M derived: sum of 2 quarters · filed 2022-05-11 | $2.00M derived: sum of 3 quarters · filed 2022-05-11 | $2.00M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $870.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $989.00K derived: sum of 2 quarters · filed 2022-02-24 | $982.00K derived: sum of 3 quarters · filed 2022-02-24 | $1.00M 10-K · filed 2022-02-24 |
| 2020-09-30 | $119.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $112.00K derived: sum of 2 quarters · filed 2021-11-10 | $134.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$7.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $15.00K 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $22.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 |